Share this:
Remember all your deadlines for grant applications and conference abstracts!
Add your email to join our free beta test:
Thank you!

Comparison of High Range and Low Range of Sensor eAG and 24-Hour Daily GF Using 3+ years of Continuous Glucose Monitoring Sensor Device Collected Data Based on GH-Method: Math-Physical Medicine (No. 458)

Engineering
Economic growth
Range (aeronautics)
Since 5/5/2018, the author utilized a continuous glucose monitoring (CGM) sensor device to collect his glucoses 96 times each day. He then calculates his average daily sensor glucoses (eAG) and sensor glucose fluctuation (GF) within a 24-hour period each. His GF is defined as the maximum glucose value minus the minimum glucose value within a day. The definition of “eAG” is the mean value of glucose data that is similar to HbA1C which is useful in diabetes control. Moreover, the glucose excursion or GF has noticeable influences on various diabetes complications. During the period of 1,218 days from 5/5/2018 through 5/31/2021, he has collected a total of 116,928 glucose data. With this big data accumulated for over 3+ years and stored on a cloud server, it is easily for him to study and observe the overall glucose changes from day to day along with the phenomenon of his daily GF changes. During the past decade, the medical community has used the term “glycemic variability (GV)” to describe the glucose excursion which involves some questionable definitions of mathematical equations with less-quantitative and somewhat inconclusive findings. It is the author’s belief that the word “variability” could mean many things to different people; therefore, he decides to apply the basic concept of glucose excursion (fluctuation) without using the defined GV equation. This will allow him to have a better understanding and achieve a deeper appreciation for the important biophysical phenomenon of “glucose fluctuation”. Many research publications have covered the importance and impact of GV or GF on diabetic macro-vascular and microvascular complications (References 16 and 17). In those publications, it has defined and “qualitatively proven” that GF does impact the macro-vascular system, including the heart and brain, as well as the micro-vascular system such as kidneys, feet, eyes, nerves, etc. This particular report adopts the author’s developed GH-Method: math-physical medicine to seek more quantitatively described results. Hopefully, it can provide a different but still accurate enough description to complement those using biochemical medicine interpretations of glucose and glucose fluctuations.


Related Papers:
DOI: 10.1089/dia.2008.0119
·
2009
Cited 27 times
The “Glucose Pentagon”: Assessing Glycemic Control of Patients with Diabetes Mellitus by a Model Integrating Different Parameters from Glucose Profiles
DOI: 10.1089/dia.2009.0185
·
2010
Cited 54 times
A Diabetes-Specific Enteral Formula Improves Glycemic Variability in Patients with Type 2 Diabetes
DOI: 10.1089/15209150050214069
·
2000
Cited 23 times
The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system.
DOI: 10.1177/193229680800200320
·
2008
Cited 8 times
Continuous Glucose Monitoring: Changing Diabetes Behavior in Real Time and Retrospectively
DOI: 10.2337/dc13-2965
·
2014
Cited 22 times
Early Hyperglycemia Detected by Continuous Glucose Monitoring in Children at Risk for Type 1 Diabetes
DOI: 10.1159/000363474
·
2015
Self-Monitoring in Diabetes: When and How Much?
MAG: 2348109118
·
2012
Influence of controlling glucose excursion on endothelin in the elderly patients with type 2 diabetes mellitus
DOI: 10.1177/1932296821992060
·
2021
Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability?
DOI: 10.31618/esu.2413-9335.2021.4.93.1568
·
2022
METHOD OF REMOTE STATUS CONTROL IN PATIENTS WITH DIABETES MELLITUS AT THE OUTPATIENT’S STAGE
DOI: 10.26226/morressier.59d51844d462b80296ca3955
·
2017
Comparison of glycemic excursion in patients with type 2 DM after treatment with Voglibose by continuous glucose monitoring device